news
Beige fat identified as potential target for blood pressure drugs
New research shows beige fat around blood vessels helps regulate blood pressure, offering potential pathways for future therapies to reduce cardiovascular risk.
List view / Grid view
Therapeutics
article
Disrupting the biologics market through innovations in macrocycle R&D
New macrocycle technologies are turning a once difficult drug class into a scalable engine for developing potent oral therapies.
news
Claudin 18.2-targeted therapy advances GI cancer treatment
A novel imaging-guided radiopharmaceutical targeting claudin 18.2 has shown that it can precisely detect and effectively treat gastric and pancreatic tumours, completely eradicating cancer in some preclinical models.
article
Rethinking drug discovery through transcription factor biology
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
article
2026: the year AI stops being optional in drug discovery
AI is moving from a supporting role into the core of drug discovery. By 2026, it is expected to shape how targets are chosen, how biology is analysed and how development decisions are made.
news
New fluorescent technology tracks drug responses in cells
Researchers have developed new innovative fluorescent labels that allow scientists to observe cellular processes with unprecedented clarity – offering a powerful tool for medicine, drug research and cell biology.
news
Functional retinal organoids improve drug testing for eye disease
Researchers have developed vascularised human retinal organoids featuring the first fully functional light-signal pathways in lab-grown human retina models, opening new possibilities for studying eye disease and testing therapies.
news
insitro expands AI drug discovery with CombinAbleAI acquisition
insitro has acquired Israeli AI therapeutics company CombinAbleAI and launched its TherML platform, creating an end-to-end, modality-agnostic system for designing small molecules, antibodies, oligonucleotides and other complex biologics.
news
New study revives long-doubted target for depression drugs
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
article
AI steps into drug safety: predicting liver injury earlier than ever before
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
news
Rare sugars point to future therapies for alcohol dependence
Researchers have identified a biological pathway linking sugar and appetite for alcohol, suggesting that rare sugars could one day form the basis of new therapies and approaches for reducing alcohol consumption and treating dependence.
news
Magnetic stimulation advances heart organoids for future therapies
Researchers have shown that applying magnetic forces to lab-grown human heart organoids enhances their maturation and vascular development, offering a more realistic model of early heart formation and the possibility of future cardiac therapies.
news
OTULIN enzyme found to drive tau and brain ageing
Researchers have discovered that the enzyme OTULIN, known for regulating the immune system, also drives the formation of tau – a protein linked to Alzheimer’s and other neurodegenerative diseases.
article
Why tau still lacks treatments and how funders are responding
Tau drives PSP, CBD and other neurodegenerative diseases, yet there are still no disease-modifying treatments. Here, Dr Glenn Harris from the Rainwater Charitable Foundation shares how a coordinated funding effort is supporting basic research to understand tau mechanisms, improve detection and progress therapeutic development.
article
Quality over quantity: drug discovery automation in 2026
Automation in 2026 is no longer judged by the volume of experiments, but by the reliability of the evidence they produce. As complex biology and tighter budgets collide, industry leaders are pivoting toward automated workflows to secure the data integrity required for confident, early-stage decision-making.
